Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer.
about
Advances in Lipidomics for Cancer Biomarkers DiscoveryThe expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancerSignificantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging.Increased phosphatidylcholine (16:0/16:0) in the folliculus lymphaticus of Warthin tumorImaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16:0/16:1) and phosphatidylcholine (18:1/20:4).Chemical mapping of the colorectal cancer microenvironment via MALDI imaging mass spectrometry (MALDI-MSI) reveals novel cancer-associated field effectsTissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry.Application of metabolomics in thyroid cancer research.Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.Matrix-assisted laser desorption/ionization mass spectrometry imaging of cell cultures for the lipidomic analysis of potential lipid markers in human breast cancer invasion.Phospholipids as cancer biomarkers: Mass spectrometry-based analysis.Matrix-assisted laser desorption/ionization imaging mass spectrometry reveals changes of phospholipid distribution in induced pluripotent stem cell colony differentiation.Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution to Chlamydia trachomatis serovar D infectivity.Lipidomics analysis revealed the phospholipid compositional changes in muscle by chronic exercise and high-fat dietProteome analysis in thyroid pathology.Rapid determination of the tumour stroma ratio in squamous cell carcinomas with desorption electrospray ionization mass spectrometry (DESI-MS): a proof-of-concept demonstration.The metabolomics and lipidomics window into thyroid cancer research.Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.Characterizing metabolic changes in human colorectal cancer.Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreasThe Distribution of Phosphatidylcholine Species in Superficial-Type Pharyngeal Carcinoma.[18F]Fluorocholine PET/CT Imaging of Liver Cancer: Radiopathologic Correlation with Tissue Phospholipid Profiling.Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer.High-resolution proteomics and metabolomics in thyroid cancer: Deciphering novel biomarkers.Cerebrospinal fluid metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients at high risk for leptomeningeal metastasis.Comparison of hepatic and serum lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and prognostic biomarkers.Global lipidomics reveals two plasma lipids as novel biomarkers for the detection of squamous cell lung cancer: A pilot study.
P2860
Q28079507-8865F65F-6619-402D-B6A3-3F78DB4685E4Q28540259-46B911F5-A2A4-4B0F-BDC8-F79D2B352234Q34001479-9AED6777-CCDF-419A-B73B-6427FFDEAF03Q34144828-288722F3-B277-420C-BD0E-6EE6DDAA9B68Q34752225-EDAC66DF-AEC9-427C-A615-396CEC93A8A6Q35013696-3108C3FD-F1BF-41E8-9386-6A4D6ABFB250Q35171220-6310DCD8-81AB-4D31-9F36-8F7660F35C56Q35564078-BC22F50E-7F72-4ECE-89FA-53BAC8C32B26Q35762498-8E32A364-7711-4850-B6CD-D532CFE66707Q35896437-AAE6FE8A-8342-4CC6-A6A3-4130DAE67DBCQ36045221-81B325D6-1732-4699-949D-2EB6B47B0064Q36183378-2E186F03-B35F-41F3-90E7-42D9CB1619F0Q37255052-353B8153-43B5-4B99-8DA5-3038E5007F8DQ37326773-4E3D6A5E-6DD0-4F8A-BD8F-70F26DD2C936Q38541463-D151FC08-E0FD-4CED-BF73-101F8C2794E4Q38695139-5CED23FC-093C-438F-8E3A-E4DE88890376Q38996666-64C8B905-2850-49F0-935C-8AB7A1A26583Q40853145-50FB15A4-F52C-427C-9AEB-903FF7DB0664Q40974589-251160F2-7947-4B45-850B-1054F2744676Q41440976-FC32A967-277D-4E39-8F48-C43BD217018EQ43161057-4E3C57EF-E730-4B9B-AFDA-08DB8BD5649FQ46469807-F7C776AE-61BD-444E-A111-9324F61271B8Q47203781-D13EA7A5-7D10-4F44-8CCA-0D38E6FFEF31Q47287949-04B256FA-FA3C-48EC-B338-A018CA45E166Q47574127-29E481C6-38F5-49AF-91A2-CC6BF561D421Q50052924-10AB0FED-787D-4F04-B8CB-78328F0922FCQ55489893-E8951645-58A7-465C-949B-8828F7A62C20
P2860
Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Increased expression of phosph ...... ) in thyroid papillary cancer.
@ast
Increased expression of phosph ...... ) in thyroid papillary cancer.
@en
Increased expression of phosphatidylcholine
@nl
type
label
Increased expression of phosph ...... ) in thyroid papillary cancer.
@ast
Increased expression of phosph ...... ) in thyroid papillary cancer.
@en
Increased expression of phosphatidylcholine
@nl
prefLabel
Increased expression of phosph ...... ) in thyroid papillary cancer.
@ast
Increased expression of phosph ...... ) in thyroid papillary cancer.
@en
Increased expression of phosphatidylcholine
@nl
P2093
P2860
P1433
P1476
Increased expression of phosph ...... ) in thyroid papillary cancer.
@en
P2093
Ichiro Tateya
Juichi Ito
Mitsutoshi Setou
Morimasa Kitamura
Noritaka Masaki
Satoshi Ohno
Seiji Ishikawa
Shigeru Hirano
Takahiro Hayasaka
Tsuyoshi Kojima
P2860
P304
P356
10.1371/JOURNAL.PONE.0048873
P407
P577
2012-11-06T00:00:00Z